PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 2502408

Candidiasis.

F Meunier
View original source ↗Export metadata ↓

Abstract

Candida spp. are the most common fungal pathogens isolated in immunocompromised hosts, particularly cancer patients. Numerous clinical manifestations of candidiasis have been recognized, including localized infection such as oropharyngeal candidiasis or focal hepatic candidiasis, and disseminated infection resulting from hematogenous spread, with or without documented fungemia. Granulocytopenic patients are particularly at risk. Candida albicans is isolated in approximately 40% of cases of fungemia, other Candida spp. now also commonly being isolated. The rate of morbidity and mortality secondary to candidiasis is still significant despite numerous attempts to develop better diagnostic techniques, and more effective means of chemoprophylaxis and therapy. Currently, new antifungal agents and galenic preparations of amphotericin B are being evaluated with the aim of improving the prognosis of candidiasis in immunocompromised hosts.

Explore related subjects

CandidaCandidiasisCentral Nervous System DiseasesEndocarditisEsophagitisGastrointestinal DiseasesHumansImmune ToleranceLiver DiseasesLung Diseases, FungalOropharynxSepsisUrinary Tract InfectionsJournal ArticleResearch Support, Non-U.S. Gov'tReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

F Meunier. 1989. Candidiasis.. https://doi.org/10.1007/bf01964058

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2026

Metabolic engineering of Candida yeasts for biotechnological applications.

Candida yeasts represent a versatile yet underexploited platform for industrial biotechnology. These yeasts utilize a remarkably broad range of carbon sources, particularly for hydrophobic carbon sources, coupled with robust growth and diverse biosynthetic capacities, making them promising hosts for sustainable production of chemicals, fuels, and proteins. Despite these advantages, industrial deployment of Candida species has been hindered by concerns regarding opportunistic pathogenicity and the historical lack of efficient genetic manipulation tools, leading to a substantial gap between metabolic potential and practical utilization. Recent advances in functional genomics, genome editing, and systems metabolic engineering are rapidly overcoming these barriers, enabling more precise and efficient strain development. In this review, we systematically summarize recent progress in the metabolic engineering of Candida species as microbial cell factories, with particular emphasis on expanding genetic toolkits, utilizting renewable and non-conventional carbon sources, and biosynthesizing high-value compounds. In addition, we propose a biosafety-oriented classification framework to support their safe industrial deployment. Finally, we discuss current challenges and emerging opportunities, emphasizing that the synergy of synthetic biology and artificial intelligence-driven design holds the key to unlocking the biotechnological potential of Candida yeasts.

Candida↗
PubMed1992

Ergosterol levels in two L-methionine-enriched mutants of the methylotrophic yeast Candida boidinii ICCF26.

Two L-methionine-enriched mutants, SN-78 and SE-57, were isolated in a sulphur-deficient medium from the methylotrophic yeast Candida boidinii ICCF26. No significant differences were detected between the L-cysteine pools of the mutants and the wild-type. In mutant strain SE-57, S-adenosylmethionine and ergosterol levels were higher than in the wild-type strain, while in the other mutant, SN-78, the levels were lower. The evidence presented would suggest that, in both the mutants and the wild-type used in this study, S-adenosylmethionine was of key importance for the accumulation of L-methionine and ergosterol.

Candida↗
PubMed1992

Structural study of a cell wall mannan-protein complex of the pathogenic yeast Candida glabrata IFO 0622 strain.

We conducted a structural analysis of the cell wall mannan-protein complex (mannan) isolated from a pathogenic yeast, Candida glabrata IFO 0622 strain. The chemical structure of mannobiose released from this mannan by treatment with 10 mM HCl at 100 degrees C for 1 h was identified as Manp beta 1-2Man. The treatment of this mannan with 100 mM NaOH at 25 degrees C for 18 h gave a mixture of alpha-1,2- and alpha-1,3-linked oligosaccharides, from tetraose to biose, and mannose. The acid- and alkali-stable mannan moiety was subjected to mild acetolysis with a 100:100:1 (v/v) mixture of (CH3CO)2O, CH3COOH, and H2SO4 at 40 degrees C for 36 h. The resultant three novel oligosaccharides, tetraose, hexaose, and heptaose, were identified as Manp beta 1-2Manp alpha 1-2Manp alpha 1-2Man, Manp alpha 1-2Manp alpha 1-2Manp alpha 1-6Manp alpha 1-2Manp alpha 1-2Man, and Manp alpha 1-3Manp alpha 1-2Manp alpha 1-2Manp alpha 1-6Manp alpha 1- 2Manp alpha 1-2Man, respectively, in addition to the three known oligosaccharides, Manp alpha 1-2Man, Manp alpha 1-2Manp alpha 1-2Man, and Manp alpha 1-3Manp alpha 1-2Manp alpha 1-2Man. A sequential analytical procedure involving partial acid hydrolysis with hot 0.3 M H2SO4, methylation, fast atom bombardment mass, and 1H NMR analyses was quite effective in the structural determination of the novel oligosaccharides. The results indicate that this mannan possesses a structure closely resembling that of Saccharomyces cerevisiae X2180-1A wild type strain, with the presence of small amounts of oligomannosyl residue, Manp beta 1-2Manp alpha 1-X, corresponding to one of the epitopes dominating serotype-A specificity of Candida spp., in addition to branches corresponding to hexaose and heptaose each containing one intermediary alpha-1,6 linkage.

Candida↗